Shop | AffiADA

Sample Collection and Preparation:
- Biological samples (e.g., serum or plasma) from patients treated with therapeutic proteins or biologics are collected for analysis.
Assay Design:
- Screening Assay: Initial testing to detect the presence of ADAs.
- Confirmatory Assay: Verification of ADA presence by competitive inhibition with the therapeutic protein.
- Titer Assay: Quantification of ADA levels to assess the immune response magnitude.
Detection:
- Plates are coated with the therapeutic protein (antigen). Samples containing ADAs bind to the coated antigen.
- Detection antibodies, often labeled with enzymes like horseradish peroxidase (HRP) or alkaline phosphatase (AP), bind to the ADAs.
- A substrate is added, and the enzyme reaction produces a measurable signal (colorimetric, fluorescent, or chemiluminescent).
Signal Measurement:
- The signal intensity, measured using a plate reader, correlates with the ADA concentration in the sample.
Data Analysis:
- Results are analyzed to determine the presence, specificity, and concentration of ADAs. This helps evaluate the immunogenic potential of the therapeutic protein.

Clinical Trials:
- Monitoring ADA formation during clinical trials of biologics to assess immunogenicity and its impact on drug efficacy and safety.
Post-Marketing Surveillance:
- Continued monitoring of ADAs in patients receiving long-term biologic therapies to ensure ongoing safety.
Biosimilar Development:
- Comparing the immunogenicity profiles of biosimilars to their reference biologics to ensure similarity and regulatory compliance.

High Sensitivity and Specificity:
- Capable of detecting low levels of ADAs, ensuring accurate assessment of immunogenicity.
Quantitative and Qualitative Analysis:
- Provides detailed information on ADA presence, concentration, and specificity.
Versatility:
- Suitable for various therapeutic proteins and biologics, making it a flexible tool for immunogenicity testing.